Insurance remains a major source of disparity for patients with testicular cancer: call for advocacy

Savannah Starr,Jj Zhang,Lin Lin,Jolie Shen,Giovanni Gamalong,Mark S. Litwin,Alexandra Drakaki,Karim Chamie
DOI: https://doi.org/10.1111/bju.16568
2024-10-27
BJU International
Abstract:Objective To evaluate the effects of socioeconomic factors, including insurance status, on treatment and survival for patients with testicular cancer. Patients and Methods We extracted a retrospective cohort from the National Cancer Database that included patients diagnosed with testicular cancer 2004–2020. Competing‐risks and Cox regression multivariate models including demographic, pathological, and socioeconomic covariates were constructed to evaluate receipt of treatment and death, respectively. Results A total of 95 955 patients with testicular cancer were identified. Compared with private insurance, Medicaid (sub‐distribution hazard ratio [SHR] 0.70, P
urology & nephrology
What problem does this paper attempt to address?